TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution conditions FORT WORTH, Texas, Sept. 11, 2024 ...

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT...

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform...